




Healthcare Industry News: HemCon Medical Technologies
News Release - January 2, 2007
HemCon Receives CE Marking for ChitoFlex Hemorrhage Control Bandage
Certification Will Allow Expanded Presence into International MarketsPORTLAND, Ore.--(HSMN NewsFeed)--HemCon Medical Technologies, Inc. has received the European Union CE marking for its unique hemorrhage control ChitoFlex bandage. With receipt of this certification, HemCon is positioned to increase distribution into countries requiring the CE marking including: Great Britain, Germany and the rest of the EU.
The ChitoFlex bandage uses the same materials and technology as the HemCon hemorrhage control bandage that has been documented to have helped save over 100 lives in Iraq and Afghanistan. ChitoFlex is a 3" x 28" strip of flexible chitosan that is designed to be stuffed into wounds that cannot be addressed by conventional methods.
"ChitoFlex was conceived and introduced in response to requests by the U.S. Military. It has already proven safe and effective in controlling severe battlefield hemorrhage." stated HemCon, Inc. President and Chief Executive Officer John W. Morgan. "This product is the platform for many new applications in civilian markets. The CE mark will now allow us to bring this life saving product to the international community."
About HemCon Medical Technologies, Inc.
HemCon Medical Technologies, Inc., founded in 2001, develops, manufactures, and markets innovative technologies to control bleeding and infection resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. The HemCon® Bandage was developed in collaboration with the Oregon Medical Laser Center and Providence St. Vincent's Hospital. HemCon's manufacturing and corporate headquarters are located in Portland, Oregon.
Source: HemCon Medical Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.